Functional Characterization of Adrenal Lesions Using [123I]IMTO-SPECT/CT
Open Access
- 1 April 2013
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 98 (4) , 1508-1518
Abstract
Context: Adrenal tumors are highly prevalent and represent a wide range of different pathological entities. Conventional imaging often provides only limited information on the origin of these lesions. Novel specific imaging methods are, therefore, of great clinical interest. Objective: We evaluated [123I]iodometomidate ([123I]IMTO) imaging for noninvasive characterization of adrenal masses. Design/Setting: This was a prospective monocentric diagnostic study in a tertiary care center. Patients and Intervention: A total of 51 patients with an adrenal lesion underwent [123I]IMTO imaging after injection of 185 MBq of [123I]IMTO. Sequential planar whole-body scans until 24 hours postinjection and single photon emission computed tomography (SPECT)/computed tomography imaging 4 to 6 hours postinjection were performed. Main Outcome Measure: Sensitivity and specificity of [123I]IMTO imaging for the noninvasive characterization of adrenal lesions were measured. Results: Adrenocortical tissue showed high and specific tracer uptake with a short investigation time and low radiation exposure. Qualitative analysis of SPECT/computed tomography data resulted in a sensitivity of 89% and a specificity of 85% for differentiating adrenocortical tumors from lesions of nonadrenocortical origin. Receiver-operating characteristic analysis of semiquantitative data revealed a sensitivity of 83% and a specificity of 86% for identification of adrenocortical lesions at a cutoff value of tumor to liver ratio of 1.3. Conclusions: [123I]IMTO is a highly specific radiotracer for imaging of adrenocortical tissue with a short investigation time and low radiation exposure. Because of the general availability of SPECT technology, [123I]IMTO scintigraphy has the potential to become a widely used tool to noninvasively characterize the biology of adrenal lesions.Keywords
This publication has 25 references indexed in Scilit:
- The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesionsNuclear Medicine Communications, 2011
- Comparison of Delayed Enhanced CT and Chemical Shift MR for Evaluating Hyperattenuating Incidental Adrenal Masses1Radiology, 2007
- The Clinically Inapparent Adrenal Mass: Update in Diagnosis and ManagementEndocrine Reviews, 2004
- Prevalence and natural history of adrenal incidentalomasEuropean Journal of Endocrinology, 2003
- Differentiation of adrenal adenomas (lipid rich and lipid poor) from nonadenomas by use of washout characteristics on delayed enhanced CT.Abdominal Radiology, 2003
- In vivo and in vitro evaluation of [ 18 F]FETO with respect to the adrenocortical and GABAergic system in ratsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Management of the Clinically Inapparent Adrenal Mass (Incidentaloma)Annals of Internal Medicine, 2003
- Adrenal Masses: Characterization with Combined Unenhanced and Delayed Enhanced CTRadiology, 2002
- Delayed Enhanced CT of Lipid-Poor Adrenal AdenomasAmerican Journal of Roentgenology, 2000
- CT time-attenuation washout curves of adrenal adenomas and nonadenomas.American Journal of Roentgenology, 1998